Correction: Standards Without Labs: Drug Development in the Psychedelic Underground

JOHN BAILEY
JOANNA KEMPNER

*Author affiliations can be found in the back matter of this article

ABSTRACT

CORRESPONDING AUTHOR:
John Bailey
Rutgers University, US
jbailey@sociology.rutgers.edu

KEYWORDS:
Citizen science; pharmaceuticals; drug development; psilocybin; psychedelics; standardization

TO CITE THIS ARTICLE:
CORRECTION

Bailey and Kempner (2022) mention that “the patent issued for the use of psilocybin as a therapy for cluster headache by the US Patent and Trademark Office fails to include the names of anyone affiliated with Clusterbusters (Sewell 2014).” Sewell (2014) draws upon Clusterbusters’ experience using psilocybin without citation but does not attempt to patent this knowledge. Schindler and D’Souza (2021) is an example of a patent application filed for using psilocybin as a therapy for cluster headache that failed to include the names of anyone affiliated with Clusterbusters.

COMPETING INTERESTS

The authors received a small grant from Porta Sophia, a non-profit psychedelic prior art library that submitted a third-party preissuance to the United States Patent and Trademark Office (USPTO) in reference to the application, US Pat. App. Ser. No. 17/168,638 entitled “Psychedelic Treatment for Headache Disorders.”

REFERENCES

